OnlyFans performer Lily Phillips exploded online after posting her pornographic video of sleeping with 101 men in one day and ...
Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...
Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...
Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...
Following a quiet stretch, the legal back-and-forth over migraine meds from Teva and Eli Lilly has resurfaced, with Teva gaining favor on appeal after a 2023 reversal of its prior patent win. The ...
Eli Lilly (LLY) reported Q4 revenue of $19.29B up 42.6% YoY, with Mounjaro generating $7.41B (up 110%) and Zepbound adding $4.26B (up 123%). Novo Nordisk (NVO) posted Q4 revenue down 7.6% YoY and cut ...
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly's tirzepatide franchise is ...
Eli Lilly (LLY) and JPMorgan (JPM) both are headed for a $1 trillion market cap, but which one is likely to get there first? Analysts have selected their favorite, based in part on the company with ...
Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...
This is the most decisive dimension in the comparison. Lilly's GLP-1 franchise is generating revenue growth that almost no large-cap company has ever sustained at this scale. Full-year 2025 revenue ...
Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...